Third Quarter 2024 Highlights
(All comparisons are against the third quarter of 2023 unless otherwise noted)
-
Sales of
$798 million , up 1% overall and flat organically -
Reported diluted EPS of
$1.57 , down 43%, and adjusted diluted EPS of$1.90 , down 10% -
Operating cash flow of
$205 million , down 9%; and 172% of net income, up from 108% -
Free cash flow of
$192 million , down 7%; and 133% of adjusted net income, up from 129% -
Completed acquisition of
Mott Corporation onSeptember 5, 2024 -
Completed a public offering of
$500 million principal amount of 4.950% Senior Notes, dueSeptember 2029
Full Year 2024 Outlook
- Full year organic sales growth is projected to decline 1% to 2% versus the prior year
-
Full year GAAP diluted EPS of
$6.65 -$6.70 vs. previous guidance of$6.85 -$6.95 . Current guidance includes purchase accounting impacts, such as acquisition-related amortization, from the acquisition ofMott Corporation -
Adjusted diluted EPS of
$7.85 -$7.90 vs. previous guidance of$7.80 -$7.90
“We are encouraged by our third quarter performance. The teams within our Fluid & Metering Technologies and Fire & Safety / Diversified Products segments drove organic growth against an uncertain economic backdrop while delivering strong margins through operational execution,” said
“Meanwhile, less than two months since completing our acquisition of Mott, the partnership is off to a fast start. Teams from other IDEX businesses are already collaborating with their Mott colleagues, designing new prototypes together that incorporate Mott’s highly engineered filtration products. Talented IDEX employees have been integrated into Mott leadership since closing, helping initiate a smooth integration,” Ashleman said. “The core advanced technology markets Mott serves, including semiconductor wafer fabrication, transformative energy solutions, medical technologies, and water purification, are advantaged to outperform over the long haul.”
“IDEX remains well-positioned, solving difficult problems with customers on the cutting edge of new technologies. We expect to continue deploying resources across our portfolio with our 8020 mindset toward growth accelerators to position us to drive long-term value creation.”
Consolidated Financial Results
|
Three Months Ended |
||||||||||
(Dollars in millions, except per share amounts) |
|
2024 |
|
|
|
2023 |
|
|
Increase (Decrease) |
||
Orders |
$ |
780.5 |
|
|
$ |
712.3 |
|
|
$ |
68.2 |
|
Change in organic orders* |
|
|
|
|
|
8 |
% |
||||
Net sales |
|
798.2 |
|
|
|
793.4 |
|
|
|
4.8 |
|
Change in organic net sales* |
|
|
|
|
|
— |
|
||||
Gross profit |
|
353.9 |
|
|
|
349.6 |
|
|
|
4.3 |
|
Adjusted gross profit* |
|
356.0 |
|
|
|
350.8 |
|
|
|
5.2 |
|
Net income attributable to IDEX |
|
119.1 |
|
|
|
209.1 |
|
|
|
(90.0 |
) |
Adjusted net income attributable to IDEX* |
|
144.1 |
|
|
|
160.6 |
|
|
|
(16.5 |
) |
Adjusted EBITDA* |
|
214.3 |
|
|
|
225.5 |
|
|
|
(11.2 |
) |
Diluted EPS attributable to IDEX |
|
1.57 |
|
|
|
2.75 |
|
|
|
(1.18 |
) |
Adjusted diluted EPS attributable to IDEX* |
|
1.90 |
|
|
|
2.12 |
|
|
|
(0.22 |
) |
Cash flows from operating activities |
|
205.3 |
|
|
|
226.6 |
|
|
|
(21.3 |
) |
Free cash flow* |
|
191.6 |
|
|
|
206.5 |
|
|
|
(14.9 |
) |
Gross margin |
|
44.3 |
% |
|
|
44.1 |
% |
|
20 bps |
||
Adjusted gross margin* |
|
44.6 |
% |
|
|
44.2 |
% |
|
40 bps |
||
Net income margin |
|
14.9 |
% |
|
|
26.3 |
% |
|
(1,140) bps |
||
Adjusted EBITDA margin* |
|
26.9 |
% |
|
|
28.4 |
% |
|
(150) bps |
||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
- Net sales increased 1% compared to the prior year period as a result of the net impact of acquisitions and divestitures. Organic net sales were flat, reflecting lower volumes in our Health & Science Technologies segment, which were mitigated by price capture across all segments.
- Gross margin of 44.3% increased 20 bps primarily due to strong price/cost, partially offset by higher employee-related costs.
-
Net income margin of 14.9% decreased 1,140 bps and reported Diluted EPS of
$1.57 decreased$1.18 , primarily as a result of the absence of the gain on sale of theMicropump, Inc. (“Micropump”) business, which occurred in the prior year period. Diluted EPS was further impacted by lower operating results as well as a higher effective tax rate. The effective tax rate in the prior year period included one-time benefits that lowered the effective tax rate, partially offset by tax recorded on the gain from theMicropump divestiture. -
Adjusted EBITDA margin of 26.9% decreased 150 bps and Adjusted diluted EPS of
$1.90 decreased$0.22 reflecting strong price/cost, which was more than offset by higher employee-related costs and lower volume. Additionally, the current year period included$3.7 million of higher transaction-related expenses in connection with the acquisition ofMott Corporation and its subsidiaries (“Mott"). -
Adjusted diluted EPS also reflects an
$0.11 impact of a higher effective tax rate as compared to the prior year period as discussed above. The adjusted effective tax rate in the prior year period excludes the gain and associated tax impacts of theMicropump divestiture.
Segment Financial Results
|
Three Months Ended |
||||||||||
(Dollars in millions) |
|
2024 |
|
|
|
2023 |
|
|
Increase (Decrease) |
||
Fluid & Metering Technologies ("FMT") |
|
|
|
|
|
||||||
Net sales |
$ |
300.8 |
|
|
$ |
301.1 |
|
|
$ |
(0.3 |
) |
Change in organic net sales* |
|
|
|
|
|
2 |
% |
||||
Adjusted EBITDA(b) |
|
98.5 |
|
|
|
103.6 |
|
|
|
(5.1 |
) |
Adjusted EBITDA margin |
|
32.8 |
% |
|
|
34.4 |
% |
|
(160) bps |
||
Health & Science Technologies ("HST") |
|
|
|
|
|
||||||
Net sales |
$ |
311.0 |
|
|
$ |
313.2 |
|
|
$ |
(2.2 |
) |
Change in organic net sales* |
|
|
|
|
|
(5 |
%) |
||||
Adjusted EBITDA(b) |
|
82.6 |
|
|
|
84.4 |
|
|
|
(1.8 |
) |
Adjusted EBITDA margin |
|
26.5 |
% |
|
|
26.9 |
% |
|
(40) bps |
||
Fire & Safety/Diversified Products ("FSDP") |
|
|
|
|
|
||||||
Net sales |
$ |
188.0 |
|
|
$ |
180.6 |
|
|
$ |
7.4 |
|
Change in organic net sales* |
|
|
|
|
|
4 |
% |
||||
Adjusted EBITDA(b) |
|
54.7 |
|
|
|
52.8 |
|
|
|
1.9 |
|
Adjusted EBITDA margin |
|
29.1 |
% |
|
|
29.3 |
% |
|
(20) bps |
||
Corporate Office and Eliminations |
|
|
|
|
|
||||||
Intersegment sales eliminations |
$ |
(1.6 |
) |
|
$ |
(1.5 |
) |
|
$ |
(0.1 |
) |
Adjusted EBITDA(b) |
|
(21.5 |
) |
|
|
(15.3 |
) |
|
|
(6.2 |
) |
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
|||||||||||
(a) Three month data includes the results of the acquisitions of STC Material Solutions ( |
|||||||||||
(b) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other. |
Fluid & Metering Technologies Segment
- Net sales were relatively flat compared to the prior year period while organic net sales were up 2%. Positive impacts of price capture were offset by the impact of divestitures. Volumes were relatively flat period over period with improvement in the industrial market and strength in our water business, offset by a down agriculture cycle and softness in the energy market.
- Adjusted EBITDA margin for the third quarter 2024 decreased primarily due to higher employee-related costs, higher discretionary spending and unfavorable mix, partially offset by price/cost.
Health & Science Technologies Segment
- Net sales for the third quarter 2024 were relatively flat while organic net sales were down 5%. Net sales were negatively impacted by lower volumes driven by continued broad based market softness. This decrease was partially offset by price capture and the positive net impact of acquisitions and divestitures.
- Adjusted EBITDA margin for the third quarter 2024 decreased primarily due to lower volume and higher employee-related costs, partially offset by price/cost, favorable operational productivity and the net accretive impact of acquisitions and divestitures.
Fire & Safety/Diversified Products Segment
- Both reported and organic net sales for the third quarter 2024 were up 4% and positively impacted by price capture and higher volumes. The benefit of key growth initiatives and strength in the aerospace market was partially offset by the cyclical nature of project sales in our North American dispensing business.
- Adjusted EBITDA margin for the third quarter 2024 decreased due to unfavorable mix. Positive price/cost offset higher employee related costs.
Mott Acquisition
On
Conference Call to be Broadcast over the Internet
IDEX will broadcast its third quarter earnings conference call over the Internet on
Forward-Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s fourth quarter 2024 and full year 2024 outlook including expected sales, expected organic sales, expected earnings per share, expected adjusted earnings per share, estimated net income and estimated adjusted EBITDA and the assumptions underlying these expectations, anticipated future acquisition behavior, resource deployment and focus and organic and inorganic growth, anticipated trends in end markets, anticipated growth initiatives, the anticipated benefits of the Company’s recent acquisitions and integration plans, including the projected EBITDA of Mott and the related impact and timing for such impact on the Company’s earnings, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.
The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the
Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the
About IDEX
For further information on
(Financial reports follow)
|
||||||||||||||
Condensed Consolidated Statements of Income |
||||||||||||||
(in millions, except per share amounts) |
||||||||||||||
(unaudited) |
||||||||||||||
|
Three Months Ended |
|
Nine Months Ended
|
|||||||||||
|
|
2024 |
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net sales |
$ |
798.2 |
|
$ |
793.4 |
|
|
$ |
2,405.9 |
|
|
$ |
2,485.0 |
|
Cost of sales |
|
444.3 |
|
|
443.8 |
|
|
|
1,327.8 |
|
|
|
1,374.9 |
|
Gross profit |
|
353.9 |
|
|
349.6 |
|
|
|
1,078.1 |
|
|
|
1,110.1 |
|
Selling, general and administrative expenses |
|
182.9 |
|
|
165.9 |
|
|
|
560.8 |
|
|
|
529.9 |
|
Restructuring expenses and asset impairments |
|
3.0 |
|
|
4.1 |
|
|
|
5.4 |
|
|
|
8.2 |
|
Operating income |
|
168.0 |
|
|
179.6 |
|
|
|
511.9 |
|
|
|
572.0 |
|
Gain on sale of business(1) |
|
0.6 |
|
|
(93.8 |
) |
|
|
(4.0 |
) |
|
|
(93.8 |
) |
Other expense (income) – net |
|
2.7 |
|
|
(2.1 |
) |
|
|
— |
|
|
|
5.6 |
|
Interest expense - net |
|
10.3 |
|
|
13.7 |
|
|
|
27.8 |
|
|
|
40.1 |
|
Income before income taxes |
|
154.4 |
|
|
261.8 |
|
|
|
488.1 |
|
|
|
620.1 |
|
Provision for income taxes |
|
35.5 |
|
|
52.8 |
|
|
|
106.7 |
|
|
|
132.8 |
|
Net income |
|
118.9 |
|
|
209.0 |
|
|
|
381.4 |
|
|
|
487.3 |
|
Net loss attributable to noncontrolling interest |
|
0.2 |
|
|
0.1 |
|
|
|
0.4 |
|
|
|
0.2 |
|
Net income attributable to IDEX |
$ |
119.1 |
|
$ |
209.1 |
|
|
$ |
381.8 |
|
|
$ |
487.5 |
|
|
|
|
|
|
|
|
|
|||||||
Earnings per Common Share: |
|
|
|
|
|
|
|
|||||||
Basic earnings per common share attributable to IDEX |
$ |
1.57 |
|
$ |
2.76 |
|
|
$ |
5.03 |
|
|
$ |
6.44 |
|
Diluted earnings per common share attributable to IDEX |
$ |
1.57 |
|
$ |
2.75 |
|
|
$ |
5.02 |
|
|
$ |
6.42 |
|
|
|
|
|
|
|
|
|
|||||||
Share Data: |
|
|
|
|
|
|
|
|||||||
Basic weighted average common shares outstanding |
|
75.7 |
|
|
75.6 |
|
|
|
75.7 |
|
|
|
75.6 |
|
Diluted weighted average common shares outstanding |
|
75.9 |
|
|
75.9 |
|
|
|
75.9 |
|
|
|
75.9 |
|
(1) |
Activity recorded during the three months ended |
|
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(in millions) |
|||||||
(unaudited) |
|||||||
|
|
|
|
||||
Assets |
|
|
|
||||
Current assets |
|
|
|
||||
Cash and cash equivalents |
$ |
633.2 |
|
|
$ |
534.3 |
|
Receivables - net |
|
475.1 |
|
|
|
427.8 |
|
Inventories - net |
|
488.2 |
|
|
|
420.8 |
|
Other current assets |
|
81.3 |
|
|
|
63.4 |
|
Total current assets |
|
1,677.8 |
|
|
|
1,446.3 |
|
Property, plant and equipment - net |
|
468.6 |
|
|
|
430.3 |
|
|
|
3,316.0 |
|
|
|
2,838.3 |
|
Intangible assets - net |
|
1,349.4 |
|
|
|
1,011.8 |
|
Other noncurrent assets |
|
155.7 |
|
|
|
138.5 |
|
Total assets |
$ |
6,967.5 |
|
|
$ |
5,865.2 |
|
|
|
|
|
||||
Liabilities and equity |
|
|
|
||||
Current liabilities |
|
|
|
||||
Trade accounts payable |
$ |
210.4 |
|
|
$ |
179.7 |
|
Accrued expenses |
|
301.2 |
|
|
|
271.5 |
|
Current portion of long-term borrowings |
|
0.6 |
|
|
|
0.6 |
|
Dividends payable |
|
52.4 |
|
|
|
48.5 |
|
Total current liabilities |
|
564.6 |
|
|
|
500.3 |
|
Long-term borrowings - net |
|
2,075.1 |
|
|
|
1,325.1 |
|
Deferred income taxes |
|
301.3 |
|
|
|
291.9 |
|
Other noncurrent liabilities |
|
208.2 |
|
|
|
206.7 |
|
Total liabilities |
|
3,149.2 |
|
|
|
2,324.0 |
|
Shareholders' equity |
|
|
|
||||
Preferred stock |
|
— |
|
|
|
— |
|
Common stock |
|
0.9 |
|
|
|
0.9 |
|
|
|
(1,176.5 |
) |
|
|
(1,187.0 |
) |
Additional paid-in capital |
|
859.9 |
|
|
|
839.0 |
|
Retained earnings |
|
4,159.3 |
|
|
|
3,934.3 |
|
Accumulated other comprehensive loss |
|
(24.7 |
) |
|
|
(45.8 |
) |
Total shareholders' equity |
|
3,818.9 |
|
|
|
3,541.4 |
|
Noncontrolling interest |
|
(0.6 |
) |
|
|
(0.2 |
) |
Total equity |
|
3,818.3 |
|
|
|
3,541.2 |
|
Total liabilities and equity |
$ |
6,967.5 |
|
|
$ |
5,865.2 |
|
|
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(in millions) |
|||||||
(unaudited) |
|||||||
|
Nine Months Ended
|
||||||
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities |
|
|
|
||||
Net income |
$ |
381.4 |
|
|
$ |
487.3 |
|
Adjustments to reconcile net income to net cash flows provided by operating activities: |
|
|
|
||||
Gain on sale of business |
|
(4.0 |
) |
|
|
(93.8 |
) |
Credit loss on note receivable from collaborative partner |
|
— |
|
|
|
7.7 |
|
Depreciation |
|
49.9 |
|
|
|
41.9 |
|
Amortization of intangible assets |
|
75.0 |
|
|
|
70.6 |
|
Share-based compensation expense |
|
20.9 |
|
|
|
18.9 |
|
Deferred income taxes |
|
0.4 |
|
|
|
(1.8 |
) |
Changes in (net of the effect from acquisitions/divestitures and foreign currency translation): |
|
|
|
||||
Receivables - net |
|
(14.5 |
) |
|
|
11.6 |
|
Inventories - net |
|
(21.6 |
) |
|
|
24.5 |
|
Other current assets |
|
(4.6 |
) |
|
|
0.3 |
|
Trade accounts payable |
|
15.3 |
|
|
|
(30.2 |
) |
Deferred revenue |
|
(4.3 |
) |
|
|
5.6 |
|
Accrued expenses |
|
(0.5 |
) |
|
|
(34.0 |
) |
Other - net |
|
2.1 |
|
|
|
7.1 |
|
Net cash flows provided by operating activities |
|
495.5 |
|
|
|
515.7 |
|
Cash flows from investing activities |
|
|
|
||||
Capital expenditures |
|
(49.6 |
) |
|
|
(68.3 |
) |
Acquisition of businesses, net of cash acquired |
|
(984.5 |
) |
|
|
(110.3 |
) |
Proceeds from sale of business, net of cash remitted |
|
45.1 |
|
|
|
110.3 |
|
Purchases of marketable securities |
|
— |
|
|
|
(24.6 |
) |
Proceeds from sale of marketable securities |
|
4.5 |
|
|
|
— |
|
Other - net |
|
(7.3 |
) |
|
|
2.9 |
|
Net cash flows used in investing activities |
|
(991.8 |
) |
|
|
(90.0 |
) |
Cash flows from financing activities |
|
|
|
||||
Borrowings under revolving credit facilities |
|
279.3 |
|
|
|
— |
|
Proceeds from issuance of long-term borrowings |
|
496.7 |
|
|
|
100.0 |
|
Payment of long-term borrowings |
|
(25.0 |
) |
|
|
(250.0 |
) |
Debt issuance costs |
|
(1.2 |
) |
|
|
— |
|
Cash dividends paid to shareholders |
|
(153.0 |
) |
|
|
(142.3 |
) |
Proceeds from share issuances, net of shares withheld for taxes |
|
10.5 |
|
|
|
7.7 |
|
Repurchases of common stock |
|
— |
|
|
|
(1.1 |
) |
Other - net |
|
(0.6 |
) |
|
|
(1.0 |
) |
Net cash flows provided by (used in) financing activities |
|
606.7 |
|
|
|
(286.7 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
6.6 |
|
|
|
(6.5 |
) |
Net increase in cash and cash equivalents and restricted cash |
|
117.0 |
|
|
|
132.5 |
|
Cash and cash equivalents at beginning of year(1) |
|
534.3 |
|
|
|
430.2 |
|
Cash and cash equivalents and restricted cash at end of period(1) |
$ |
651.3 |
|
|
$ |
562.7 |
|
(1) |
Includes |
|
|||||||||||
Company and Segment Financial Information |
|||||||||||
(in millions) |
|||||||||||
(unaudited) |
|||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
Fluid & Metering Technologies |
|
|
|
|
|
|
|
||||
Depreciation |
$ |
4.3 |
|
$ |
3.1 |
|
$ |
12.9 |
|
$ |
10.3 |
Amortization of intangible assets |
|
5.2 |
|
|
5.6 |
|
|
15.7 |
|
|
17.3 |
Restructuring expenses and asset impairments |
|
1.0 |
|
|
1.7 |
|
|
1.6 |
|
|
2.4 |
Health & Science Technologies |
|
|
|
|
|
|
|
||||
Depreciation |
$ |
10.6 |
|
$ |
9.0 |
|
$ |
29.5 |
|
$ |
24.1 |
Amortization of intangible assets |
|
19.7 |
|
|
16.7 |
|
|
54.6 |
|
|
48.5 |
Restructuring expenses and asset impairments |
|
1.7 |
|
|
1.5 |
|
|
3.3 |
|
|
4.5 |
Fire & Safety/Diversified Products |
|
|
|
|
|
|
|
||||
Depreciation |
$ |
2.2 |
|
$ |
2.3 |
|
$ |
6.7 |
|
$ |
6.7 |
Amortization of intangible assets |
|
1.6 |
|
|
1.5 |
|
|
4.7 |
|
|
4.8 |
Restructuring expenses and asset impairments |
|
0.1 |
|
|
0.4 |
|
|
0.2 |
|
|
0.8 |
Corporate Office and Eliminations |
|
|
|
|
|
|
|
||||
Depreciation |
$ |
0.3 |
|
$ |
0.3 |
|
$ |
0.8 |
|
$ |
0.8 |
Restructuring expenses and asset impairments |
|
0.2 |
|
|
0.5 |
|
|
0.3 |
|
|
0.5 |
Total IDEX |
|
|
|
|
|
|
|
||||
Depreciation |
$ |
17.4 |
|
$ |
14.7 |
|
$ |
49.9 |
|
$ |
41.9 |
Amortization of intangible assets |
|
26.5 |
|
|
23.8 |
|
|
75.0 |
|
|
70.6 |
Restructuring expenses and asset impairments |
|
3.0 |
|
|
4.1 |
|
|
5.4 |
|
|
8.2 |
Non-GAAP Measures of Financial Performance
The Company prepares its public financial statements in conformity with accounting principles generally accepted in
All table footnotes can be found at the end of this Non-GAAP Measures section. There were no adjustments to GAAP financial performance metrics other than the items noted below.
- Organic orders and net sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation.
- Adjusted gross profit is calculated as gross profit plus fair value inventory step-up charges.
- Adjusted gross margin is calculated as adjusted gross profit divided by net sales.
- Adjusted net income attributable to IDEX is calculated as net income attributable to IDEX plus fair value inventory step-up charges, plus restructuring expenses and asset impairments, less the gain on sale of a business, plus the credit loss on a note receivable from a collaborative partner, plus acquisition-related intangible asset amortization, all net of the statutory tax expense or benefit.
- Adjusted diluted EPS attributable to IDEX is calculated as adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding.
- Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, taxes, depreciation and amortization, or consolidated EBITDA, less the gain on sale of a business, plus fair value inventory step-up charges, plus restructuring expenses and asset impairments, plus the credit loss on a note receivable from a collaborative partner.
- Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by net sales.
- Free cash flow is calculated as cash flows from operating activities less capital expenditures. Free cash flow conversion is calculated as free cash flow divided by adjusted net income attributable to IDEX.
Table 1: Reconciliations of the Change in |
|||||||||||
|
|
|
|
|
|
|
|
||||
|
FMT |
|
HST |
|
FSDP |
|
IDEX |
||||
|
Three Months Ended |
||||||||||
Change in net sales |
— |
% |
|
(1 |
%) |
|
4 |
% |
|
1 |
% |
Less: |
|
|
|
|
|
|
|
||||
Net impact from acquisitions/divestitures(1) |
(3 |
%) |
|
4 |
% |
|
— |
% |
|
1 |
% |
Impact from foreign currency |
1 |
% |
|
— |
% |
|
— |
% |
|
— |
% |
Change in organic net sales |
2 |
% |
|
(5 |
%) |
|
4 |
% |
|
— |
% |
|
|
|
|
|
|
|
|
||||
|
Nine Months Ended |
||||||||||
Change in net sales |
(1 |
%) |
|
(8 |
%) |
|
2 |
% |
|
(3 |
%) |
Less: |
|
|
|
|
|
|
|
||||
Net impact from acquisitions/divestitures(1) |
(1 |
%) |
|
2 |
% |
|
— |
% |
|
— |
% |
Impact from foreign currency |
— |
% |
|
— |
% |
|
— |
% |
|
— |
% |
Change in organic net sales |
— |
% |
|
(10 |
%) |
|
2 |
% |
|
(3 |
%) |
Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions) |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Gross profit |
$ |
353.9 |
|
|
$ |
349.6 |
|
|
$ |
1,078.1 |
|
|
$ |
1,110.1 |
|
Fair value inventory step-up charge |
|
2.1 |
|
|
|
1.2 |
|
|
|
4.6 |
|
|
|
1.2 |
|
Adjusted gross profit |
$ |
356.0 |
|
|
$ |
350.8 |
|
|
$ |
1,082.7 |
|
|
$ |
1,111.3 |
|
|
|
|
|
|
|
|
|
||||||||
Net sales |
$ |
798.2 |
|
|
$ |
793.4 |
|
|
$ |
2,405.9 |
|
|
$ |
2,485.0 |
|
|
|
|
|
|
|
|
|
||||||||
Gross margin |
|
44.3 |
% |
|
|
44.1 |
% |
|
|
44.8 |
% |
|
|
44.7 |
% |
Adjusted gross margin |
|
44.6 |
% |
|
|
44.2 |
% |
|
|
45.0 |
% |
|
|
44.7 |
% |
Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, other than per share amounts) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Reported net income attributable to IDEX |
|
$ |
119.1 |
|
|
$ |
209.1 |
|
|
$ |
381.8 |
|
|
$ |
487.5 |
|
Fair value inventory step-up charge |
|
|
2.1 |
|
|
|
1.2 |
|
|
|
4.6 |
|
|
|
1.2 |
|
Tax impact on fair value inventory step-up charge |
|
|
(0.5 |
) |
|
|
(0.3 |
) |
|
|
(1.0 |
) |
|
|
(0.3 |
) |
Restructuring expenses and asset impairments |
|
|
3.0 |
|
|
|
4.1 |
|
|
|
5.4 |
|
|
|
8.2 |
|
Tax impact on restructuring expenses and asset impairments |
|
|
(0.7 |
) |
|
|
(0.9 |
) |
|
|
(1.3 |
) |
|
|
(1.8 |
) |
Gain on sale of business(2) |
|
|
0.6 |
|
|
|
(93.8 |
) |
|
|
(4.0 |
) |
|
|
(93.8 |
) |
Tax impact on gain of sale of business |
|
|
— |
|
|
|
22.7 |
|
|
|
— |
|
|
|
22.7 |
|
Credit loss on note receivable from collaborative partner(3) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7.7 |
|
Tax impact on credit loss on note receivable from collaborative partner |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1.6 |
) |
Acquisition-related intangible asset amortization |
|
|
26.5 |
|
|
|
23.8 |
|
|
|
75.0 |
|
|
|
70.6 |
|
Tax impact on acquisition-related intangible asset amortization |
|
|
(6.0 |
) |
|
|
(5.3 |
) |
|
|
(17.1 |
) |
|
|
(15.8 |
) |
Adjusted net income attributable to IDEX |
|
$ |
144.1 |
|
|
$ |
160.6 |
|
|
$ |
443.4 |
|
|
$ |
484.6 |
|
|
|
|
|
|
|
|
|
|
||||||||
Reported diluted EPS attributable to IDEX |
|
$ |
1.57 |
|
|
$ |
2.75 |
|
|
$ |
5.02 |
|
|
$ |
6.42 |
|
Fair value inventory step-up charge |
|
|
0.03 |
|
|
|
0.02 |
|
|
|
0.06 |
|
|
|
0.02 |
|
Tax impact on fair value inventory step-up charge |
|
|
— |
|
|
|
— |
|
|
|
(0.01 |
) |
|
|
— |
|
Restructuring expenses and asset impairments |
|
|
0.04 |
|
|
|
0.06 |
|
|
|
0.07 |
|
|
|
0.11 |
|
Tax impact on restructuring expenses and asset impairments |
|
|
(0.01 |
) |
|
|
(0.01 |
) |
|
|
(0.02 |
) |
|
|
(0.03 |
) |
Gain on sale of business(2) |
|
|
0.01 |
|
|
|
(1.24 |
) |
|
|
(0.05 |
) |
|
|
(1.24 |
) |
Tax impact on gain of sale of business |
|
|
— |
|
|
|
0.30 |
|
|
|
— |
|
|
|
0.30 |
|
Credit loss on note receivable from collaborative partner(3) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.10 |
|
Tax impact on credit loss on note receivable from collaborative partner |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(0.02 |
) |
Acquisition-related intangible asset amortization |
|
|
0.35 |
|
|
|
0.31 |
|
|
|
0.99 |
|
|
|
0.93 |
|
Tax impact on acquisition-related intangible asset amortization |
|
|
(0.09 |
) |
|
|
(0.07 |
) |
|
|
(0.22 |
) |
|
|
(0.21 |
) |
Adjusted diluted EPS attributable to IDEX |
|
$ |
1.90 |
|
|
$ |
2.12 |
|
|
$ |
5.84 |
|
|
$ |
6.38 |
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted average shares outstanding |
|
|
75.9 |
|
|
|
75.9 |
|
|
|
75.9 |
|
|
|
75.9 |
|
Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions) |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Reported net income |
$ |
118.9 |
|
|
$ |
209.0 |
|
|
$ |
381.4 |
|
|
$ |
487.3 |
|
Provision for income taxes |
|
35.5 |
|
|
|
52.8 |
|
|
|
106.7 |
|
|
|
132.8 |
|
Interest expense - net |
|
10.3 |
|
|
|
13.7 |
|
|
|
27.8 |
|
|
|
40.1 |
|
Gain on sale of business(2) |
|
0.6 |
|
|
|
(93.8 |
) |
|
|
(4.0 |
) |
|
|
(93.8 |
) |
Depreciation |
|
17.4 |
|
|
|
14.7 |
|
|
|
49.9 |
|
|
|
41.9 |
|
Amortization |
|
26.5 |
|
|
|
23.8 |
|
|
|
75.0 |
|
|
|
70.6 |
|
Fair value inventory step-up charges |
|
2.1 |
|
|
|
1.2 |
|
|
|
4.6 |
|
|
|
1.2 |
|
Restructuring expenses and asset impairments |
|
3.0 |
|
|
|
4.1 |
|
|
|
5.4 |
|
|
|
8.2 |
|
Credit loss on note receivable from collaborative partner(3) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7.7 |
|
Adjusted EBITDA |
$ |
214.3 |
|
|
$ |
225.5 |
|
|
$ |
646.8 |
|
|
$ |
696.0 |
|
|
|
|
|
|
|
|
|
||||||||
Adjusted EBITDA Components: |
|
|
|
|
|
|
|
||||||||
FMT |
$ |
98.5 |
|
|
$ |
103.6 |
|
|
$ |
311.6 |
|
|
$ |
323.9 |
|
HST |
|
82.6 |
|
|
|
84.4 |
|
|
|
248.2 |
|
|
|
278.8 |
|
FSDP |
|
54.7 |
|
|
|
52.8 |
|
|
|
159.9 |
|
|
|
157.0 |
|
Corporate and other |
|
(21.5 |
) |
|
|
(15.3 |
) |
|
|
(72.9 |
) |
|
|
(63.7 |
) |
Total Adjusted EBITDA |
$ |
214.3 |
|
|
$ |
225.5 |
|
|
$ |
646.8 |
|
|
$ |
696.0 |
|
|
|
|
|
|
|
|
|
||||||||
Net sales |
$ |
798.2 |
|
|
$ |
793.4 |
|
|
$ |
2,405.9 |
|
|
$ |
2,485.0 |
|
|
|
|
|
|
|
|
|
||||||||
Net income margin |
|
14.9 |
% |
|
|
26.3 |
% |
|
|
15.9 |
% |
|
|
19.6 |
% |
Adjusted EBITDA margin |
|
26.9 |
% |
|
|
28.4 |
% |
|
|
26.9 |
% |
|
|
28.0 |
% |
Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions) |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities |
$ |
205.3 |
|
|
$ |
226.6 |
|
|
$ |
495.5 |
|
|
$ |
515.7 |
|
Less: Capital expenditures |
|
13.7 |
|
|
|
20.1 |
|
|
|
49.6 |
|
|
|
68.3 |
|
Free cash flow |
$ |
191.6 |
|
|
$ |
206.5 |
|
|
$ |
445.9 |
|
|
$ |
447.4 |
|
|
|
|
|
|
|
|
|
||||||||
Reported net income attributable to IDEX |
$ |
119.1 |
|
|
$ |
209.1 |
|
|
$ |
381.8 |
|
|
$ |
487.5 |
|
Adjusted net income attributable to IDEX |
|
144.1 |
|
|
|
160.6 |
|
|
|
443.4 |
|
|
|
484.6 |
|
|
|
|
|
|
|
|
|
||||||||
Operating cash flow conversion |
|
172 |
% |
|
|
108 |
% |
|
|
130 |
% |
|
|
106 |
% |
Free cash flow conversion |
|
133 |
% |
|
|
129 |
% |
|
|
101 |
% |
|
|
92 |
% |
Table 6: Reconciliation of Estimated 2024 Change in |
|||||||||||
|
Guidance |
||||||||||
|
Fourth Quarter 2024 |
|
Full Year 2024 |
||||||||
|
Low End |
|
High End |
|
Low End |
|
High End |
||||
Change in net sales |
10 |
% |
|
11 |
% |
|
— |
% |
|
1 |
% |
Less: |
|
|
|
|
|
|
|
||||
Net impact from acquisitions/divestitures |
6 |
% |
|
6 |
% |
|
2 |
% |
|
2 |
% |
Impact from foreign currency |
1 |
% |
|
1 |
% |
|
— |
% |
|
— |
% |
Change in organic net sales |
3 |
% |
|
4 |
% |
|
(2 |
%) |
|
(1 |
%) |
Table 7: Reconciliation of Estimated 2024 Diluted EPS Attributable to IDEX to Adjusted Diluted EPS Attributable to IDEX |
||||
|
|
Guidance |
||
|
|
Fourth Quarter 2024 |
|
Full Year 2024 |
Estimated diluted EPS attributable to IDEX |
|
|
|
|
Fair value inventory step-up charge |
|
0.05 |
|
0.12 |
Tax impact on fair value inventory step-up charge |
|
(0.01) |
|
(0.03) |
Restructuring expenses and asset impairments |
|
— |
|
0.08 |
Tax impact on restructuring expenses and asset impairments |
|
— |
|
(0.02) |
Gain on sale of business |
|
— |
|
(0.05) |
Tax impact on gain of sale of business |
|
— |
|
— |
Acquisition-related intangible asset amortization |
|
0.43 |
|
1.42 |
Tax impact on acquisition-related intangible asset amortization |
|
(0.10) |
|
(0.32) |
Estimated adjusted diluted EPS attributable to IDEX |
|
|
|
|
Table 8: Reconciliation of Estimated 2024 Net Income to Adjusted EBITDA (dollars in millions)
|
Guidance |
||||||||||||||
|
Fourth Quarter 2024 |
|
Full Year 2024 |
||||||||||||
|
Low End |
|
High End |
|
Low End |
|
High End |
||||||||
Estimated Reported net income |
$ |
123.1 |
|
|
$ |
127.4 |
|
|
$ |
504.5 |
|
|
$ |
508.8 |
|
Provision for income taxes |
|
38.0 |
|
|
|
39.4 |
|
|
|
144.7 |
|
|
|
146.1 |
|
Interest expense - net |
|
18.2 |
|
|
|
18.2 |
|
|
|
46.0 |
|
|
|
46.0 |
|
Gain on sale of business |
|
— |
|
|
|
— |
|
|
|
(4.0 |
) |
|
|
(4.0 |
) |
Depreciation |
|
19.3 |
|
|
|
19.3 |
|
|
|
69.2 |
|
|
|
69.2 |
|
Amortization of intangible assets |
|
32.6 |
|
|
|
32.6 |
|
|
|
107.6 |
|
|
|
107.6 |
|
Fair value inventory step-up charge |
|
4.2 |
|
|
|
4.2 |
|
|
|
8.8 |
|
|
|
8.8 |
|
Restructuring expenses and asset impairments |
|
0.4 |
|
|
|
0.4 |
|
|
|
5.8 |
|
|
|
5.8 |
|
Estimated Adjusted EBITDA |
$ |
235.8 |
|
|
$ |
241.5 |
|
|
$ |
882.6 |
|
|
$ |
888.3 |
|
|
|
|
|
|
|
|
|
||||||||
Estimated Net sales |
$ |
874.3 |
|
|
$ |
882.3 |
|
|
$ |
3,280.2 |
|
|
$ |
3,288.2 |
|
|
|
|
|
|
|
|
|
||||||||
Estimated Net income margin |
|
14.1 |
% |
|
|
14.4 |
% |
|
|
15.4 |
% |
|
|
15.5 |
% |
Estimated Adjusted EBITDA margin |
|
27.0 |
% |
|
|
27.4 |
% |
|
|
26.9 |
% |
|
|
27.0 |
% |
(1) |
Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture. |
|
(2) |
Activity recorded during the three months ended |
|
(3) |
Represents a reserve on an investment with a collaborative partner recorded in Other expense (income) – net during the nine months ended |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029769149/en/
Investor Contact:
Vice President FP&A and Investor Relations
(847) 498-7070
Source: